(MENAFN- Straits Research)
Oncology Biosimilar Market Size & Growth Analysis
The global oncology biosimilar market size was valued at USD 8 billion in 2025 and is projected to grow from USD 9.48 billion in 2026 to USD 36.86 billion by 2034, registering a CAGR of 18.5% during the forecast period from 2026 to 2034. North America dominated the oncology biosimilar market with a market share of 38% in 2025.
Oncology biosimilars are biologic medicines developed to be highly similar to approved reference biologics used in the treatment of cancer, with no clinically meaningful differences in safety, efficacy, or quality. They are manufactured using living cells and undergo rigorous regulatory evaluation to ensure comparable therapeutic performance. These products help expand patient access to advanced cancer therapies while supporting cost efficiency and broader adoption of biologic treatments.
Oncology Biosimilar Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 8.00 Billion
2026 Market Size: USD 9.48 Billion
2034 Projected Market Size: USD 36.90 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 18.5%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 38%
Fastest-Growing Region: Asia Pacific
Asia Pacific CAGR (2026–2034): 18.7%
Segment Insights
By Product Type
Leading Segment: Monoclonal Antibodies (mAbs)
Market Share in 2025: 52%
By Cancer Type
Fastest growing segment: Lung Cancer
CAGR: 17.1% (2026-2034)
By Route Of Administration
Leading Segment: Intravenous (IV)
Market Share in 2025: 17.1%
By Distribution Channel
Fastest growing segment: Online Pharmacies
CAGR: 19.3% (2026-2034)
Download a Free Sample To learn more about this report,
Oncology Biosimilar Market Trends
Rapid Increase in Adoption of Biosimilars for Cancer Treatment
Oncology biosimilars are gaining broader acceptance as healthcare providers become more familiar with their clinical performance, regulatory standards, and potential economic benefits. Biosimilars for widely used cancer biologics are increasingly being incorporated into treatment pathways, particularly for therapies with established clinical experience and multiple approved alternatives. Greater physician confidence and institutional experience are helping biosimilars move from limited adoption toward a more significant role in routine oncology care.
In March 2026, a JAMA study reported that biosimilar use among hospitals increased substantially between 2020 and 2024, reaching 93% of bevacizumab use, 87% of trastuzumab use, and 84% of rituximab use by 2024.
Expansion of Biosimilar Competition Across Major Oncology Biologics
The oncology biosimilar landscape is expanding as additional manufacturers develop alternatives to high-value reference biologics used across cancer treatment. Increasing competition is providing healthcare systems with more purchasing options and encouraging manufacturers to compete through pricing, supply reliability, manufacturing capacity, and market access strategies. The expansion of biosimilar portfolios is also increasing the potential for competition across multiple oncology treatment categories.
In November 2025, the U.S. Food and Drug Administration approved the first biosimilar to pertuzumab, with the product designated as interchangeable with the reference therapy, expanding biosimilar competition in breast cancer treatment.
Oncology Biosimilar Market Dynamics
Market Drivers
Rising Pressure to Reduce Cancer Treatment Costs Supports Biosimilar Demand
The high cost of biologic cancer therapies is encouraging healthcare providers, insurers, and patients to consider biosimilars as cost-efficient treatment alternatives. Greater use of biosimilars can increase competition among biologic products, reduce spending on selected therapies, and potentially allow healthcare resources to be redirected toward other areas of cancer care. As healthcare systems continue seeking ways to improve affordability without compromising treatment standards, the economic value of oncology biosimilars is strengthening their adoption.
In August 2026, a JAMA Oncology study found that cancer patients using biosimilars exclusively had average monthly payer costs that were $3,820 lower and average monthly out-of-pocket costs that were $39.50 lower than patients using the corresponding originator biologics exclusively.
Market Restraints
Complex Reimbursement Structures Can Limit Biosimilar Adoption
Reimbursement mechanisms can influence whether providers and healthcare institutions have sufficient financial incentives to select biosimilars over reference biologics. Differences between acquisition costs, reimbursement rates, payer policies, and site-of-care economics can create uneven incentives across hospitals and physician practices. These financial considerations can slow adoption even when biosimilars offer lower acquisition prices and comparable clinical performance.
In March 2026, a JAMA study found that oncology biosimilar acquisition prices declined more rapidly than reimbursement prices between 2020 and 2024, highlighting the influence of reimbursement structures on provider economics and adoption.
Market Opportunities
Emergence of New Biosimilar Candidates Creates Opportunities Across High-Value Oncology Therapies
The expiration or reduction of exclusivity barriers around widely used oncology biologics is creating opportunities for manufacturers to develop additional biosimilar products. High-value therapies with substantial treatment volumes can provide attractive opportunities for biosimilar developers seeking to expand oncology portfolios and healthcare systems seeking additional sources of competition. Increasing development activity can also broaden patient access to biologic-based cancer treatment by introducing additional products into established therapeutic categories.
In September 2026, Cipla announced a partnership with Qilu Pharmaceutical to commercialize a biosimilar version of pembrolizumab for the U.S. market, demonstrating continued manufacturer interest in developing alternatives to high-value oncology biologics.
Market Challenges
Uneven Physician and Patient Confidence Can Slow Oncology Biosimilar Switching
Although biosimilars are required to demonstrate high similarity to their reference products, differences in familiarity, clinical experience, and perceptions of treatment risk can influence prescribing and patient acceptance. Concerns may be particularly relevant when switching patients who are already receiving an established biologic therapy. Continued education, transparent clinical evidence, institutional protocols, and clear communication about biosimilar quality are therefore important for achieving consistent adoption across oncology settings.
In December 2025, a global analysis of oncology-related biosimilar use found that uptake varied considerably between countries, with the United States ranking below the median of the 13 countries studied, indicating persistent differences in adoption across healthcare systems.
Oncology Biosimilar Market Segmentation
By Product Type
Monoclonal Antibodies (mAbs) Dominated the Market with 52% Share in 2025
The Monoclonal Antibodies (mAbs) segment accounted for the largest share of the global oncology biosimilar market at 52% in 2025, driven by the high adoption of biosimilar versions of blockbuster cancer therapies, increasing regulatory approvals, and growing demand for cost-effective biologic treatments.
Request Customization to receive a tailored report.
By Cancer Type
Lung Cancer is Projected to Register the Fastest Growth at a CAGR of 17.1%
The Lung Cancer segment is expected to expand at the highest CAGR of 17.1% during 2026–2034, supported by the rising incidence of lung cancer, increasing use of targeted biologic therapies, and wider availability of biosimilars that improve treatment affordability.
By Route of Administration
Intravenous (IV) Dominated the Market with 68% Share in 2025
The Intravenous (IV) segment held the largest share of the global oncology biosimilar market at 68% in 2025, owing to the widespread use of intravenous biologics in hospital-based cancer treatment, established clinical protocols, and the need for supervised administration.
By Distribution Channel
Online Pharmacies are Projected to Register the Fastest Growth at a CAGR of 19.3%
The Online Pharmacies segment is anticipated to witness the fastest growth, registering a CAGR of 19.3% during 2026–2034, driven by expanding digital healthcare platforms, increasing patient preference for home delivery services, improved access to specialty medicines, and the growing adoption of e-pharmacy services.
Speak to an Analyst to discuss market opportunities.
Oncology Biosimilar Regional Analysis
North America Oncology Biosimilar Market Analysis
North America dominated the global oncology biosimilar market with a 38.0% market share, valued at USD 3.04 billion in 2025. The region benefits from advanced oncology care infrastructure, favorable regulatory pathways for biosimilar approvals, increasing adoption of cost-effective biologics, and strong reimbursement support. Rising cancer prevalence, growing healthcare expenditure, and expanding physician confidence in biosimilars continue to accelerate market growth across the region.
United States Oncology Biosimilar Market Insights
The United States accounted for an estimated USD 2.58 billion of the market in 2025, making it the largest contributor in North America. Growth is driven by increasing biosimilar approvals, expanding use of biosimilar monoclonal antibodies in cancer treatment, strong payer support, and the presence of major pharmaceutical companies investing in oncology biosimilars.
Canada Oncology Biosimilar Market Insights
Canada generated an estimated USD 0.46 billion in 2025. Rising healthcare investments, expanding biosimilar adoption programs, increasing demand for affordable cancer therapies, and supportive government reimbursement initiatives continue to drive market growth across the country.
Europe Oncology Biosimilar Market Analysis
Europe accounted for 31.0% of the global oncology biosimilar market, reaching USD 2.48 billion in 2025. The market is supported by well-established biosimilar regulatory frameworks, high physician acceptance, increasing healthcare cost-containment strategies, and widespread adoption of biosimilar oncology products. Continued investment in biologic manufacturing and favorable reimbursement policies further support regional growth.
United Kingdom Oncology Biosimilar Market Insights
The United Kingdom represented an estimated USD 0.50 billion in 2025. The country's market is driven by NHS initiatives promoting biosimilar adoption, increasing oncology treatment demand, expanding access to biologic therapies, and efforts to reduce healthcare costs through biosimilar utilization.
Germany Oncology Biosimilar Market Insights
Germany led the European market with an estimated value of USD 0.69 billion in 2025. The country's advanced healthcare infrastructure, strong biosimilar uptake, growing cancer burden, and favorable reimbursement environment continue to support sustained market expansion.
Asia Pacific Oncology Biosimilar Market Analysis
Asia Pacific accounted for 22.0% of the global oncology biosimilar market, valued at USD 1.76 billion in 2025, and is projected to register the fastest CAGR of 18.7% during the forecast period. Rising cancer incidence, expanding healthcare infrastructure, increasing government support for biosimilars, and growing domestic biologics manufacturing are accelerating market growth across the region.
Japan Oncology Biosimilar Market Insights
Japan generated an estimated USD 0.32 billion in 2025. The country's aging population, increasing cancer prevalence, supportive biosimilar policies, and expanding adoption of advanced biologic therapies continue to fuel market growth.
China Oncology Biosimilar Market Insights
China accounted for an estimated USD 0.74 billion in 2025, making it the largest market in the Asia Pacific. Government healthcare reforms, increasing domestic biosimilar production, expanding oncology treatment access, and rising investments in biopharmaceutical research continue to drive strong market growth.
Middle East & Africa Oncology Biosimilar Market Analysis
The Middle East & Africa represented 4.0% of the global oncology biosimilar market, totaling USD 0.32 billion in 2025. Increasing healthcare investments, improving access to cancer treatment, expanding adoption of biosimilars, and growing awareness of affordable biologic therapies are supporting regional market growth.
UAE Oncology Biosimilar Market Insights
The United Arab Emirates (UAE) accounted for an estimated USD 0.08 billion in 2025. The country's market is driven by government investments in oncology care, expanding specialty healthcare facilities, increasing access to biosimilar therapies, and growing demand for cost-effective cancer treatments.
Africa Oncology Biosimilar Market Insights
Africa is witnessing steady growth in the oncology biosimilar market, supported by improving oncology care infrastructure, increasing cancer awareness, expanding healthcare investments, and greater availability of affordable biologic medicines. Countries such as South Africa, Egypt, and Kenya are strengthening cancer treatment capabilities, creating long-term growth opportunities for oncology biosimilar manufacturers.
Unlock Regional Insights to access country-level data, & regional trends.
Europe Oncology Biosimilar Market Analysis
Europe accounted for 31.0% of the global oncology biosimilar market, reaching USD 2.48 billion in 2025. The market is supported by well-established biosimilar regulatory frameworks, high physician acceptance, increasing healthcare cost-containment strategies, and widespread adoption of biosimilar oncology products. Continued investment in biologic manufacturing and favorable reimbursement policies further support regional growth.
United Kingdom Oncology Biosimilar Market Insights
The United Kingdom represented an estimated USD 0.50 billion in 2025. The country's market is driven by NHS initiatives promoting biosimilar adoption, increasing oncology treatment demand, expanding access to biologic therapies, and efforts to reduce healthcare costs through biosimilar utilization.
Germany Oncology Biosimilar Market Insights
Germany led the European market with an estimated value of USD 0.69 billion in 2025. The country's advanced healthcare infrastructure, strong biosimilar uptake, growing cancer burden, and favorable reimbursement environment continue to support sustained market expansion.
Asia Pacific Oncology Biosimilar Market Analysis
Asia Pacific accounted for 22.0% of the global oncology biosimilar market, valued at USD 1.76 billion in 2025, and is projected to register the fastest CAGR of 18.7% during the forecast period. Rising cancer incidence, expanding healthcare infrastructure, increasing government support for biosimilars, and growing domestic biologics manufacturing are accelerating market growth across the region.
Japan Oncology Biosimilar Market Insights
Japan generated an estimated USD 0.32 billion in 2025. The country's aging population, increasing cancer prevalence, supportive biosimilar policies, and expanding adoption of advanced biologic therapies continue to fuel market growth.
China Oncology Biosimilar Market Insights
China accounted for an estimated USD 0.74 billion in 2025, making it the largest market in the Asia Pacific. Government healthcare reforms, increasing domestic biosimilar production, expanding oncology treatment access, and rising investments in biopharmaceutical research continue to drive strong market growth.
Middle East & Africa Oncology Biosimilar Market Analysis
The Middle East & Africa represented 4.0% of the global oncology biosimilar market, totaling USD 0.32 billion in 2025. Increasing healthcare investments, improving access to cancer treatment, expanding adoption of biosimilars, and growing awareness of affordable biologic therapies are supporting regional market growth.
UAE Oncology Biosimilar Market Insights
The United Arab Emirates (UAE) accounted for an estimated USD 0.08 billion in 2025. The country's market is driven by government investments in oncology care, expanding specialty healthcare facilities, increasing access to biosimilar therapies, and growing demand for cost-effective cancer treatments.
Africa Oncology Biosimilar Market Insights
Africa is witnessing steady growth in the oncology biosimilar market, supported by improving oncology care infrastructure, increasing cancer awareness, expanding healthcare investments, and greater availability of affordable biologic medicines. Countries such as South Africa, Egypt, and Kenya are strengthening cancer treatment capabilities, creating long-term growth opportunities for oncology biosimilar manufacturers.
List of Key and Emerging Players in Oncology Biosimilar Market
Pfizer Inc.
Amgen Inc.
Novartis International AG
Biocon Ltd.
Reddy's Laboratories
Samsung Bioepis
Mylan N.V. (now part of Viatris)
Allergan (AbbVie)
STADA Arzneimittel AG
Apotex Inc.
Roche (via biosimilar affiliates)
Sandoz (Novartis division)
Celltrion Inc.
Bio-Thera Solutions
Organon (via acquired biosimilar rights)
Teva Pharmaceuticals
Key Industry Developments
June 2026: Amgen expanded its oncology biosimilar portfolio with continued commercialization of advanced biosimilar cancer therapies across global markets. The expansion strengthens access to lower-cost alternatives for biologic oncology treatments.
March 2026: Celltrion expanded its oncology biosimilar pipeline with regulatory submissions and commercialization activities for antibody-based cancer biosimilars. The company focused on increasing availability of cost-effective biologic treatments in key markets.
January 2026: Samsung Bioepis expanded its oncology biosimilar portfolio with additional launches and regulatory approvals across international markets. The company continued strengthening its position in antibody-based biosimilars for cancer treatment.
October 2025: Biocon Biologics expanded access to its oncology biosimilars through additional market launches and healthcare partnerships. The initiative supports wider availability of affordable targeted cancer therapies.
Report Scope
Comments
No comment